Article

Risk of death due to heart and vascular disease higher in black patients with glaucoma

According to the Barbados Eye Studies, black people treated for glaucoma are at increased risk of dying from heart and vascular disease, particularly those treated with timolol maleate eye drops.

New York-According to the Barbados Eye Studies, black people treated for glaucoma are at increased risk of dying from heart and vascular disease, particularly those treated with timolol maleate eye drops.

"Glaucoma is one of the leading causes of visual impairment worldwide," Suh-Yuh Wu and colleagues noted in the Archives of Ophthalmology. "The most common type, primary open-angle glaucoma, is especially prevalent in populations of African origin, in which it is the foremost cause of blindness."

More than 90% of the Barbados population is black, life expectancy is high, and health care is free. The study evaluated long-term mortality rates among 4,092 subjects who had eye examinations between 1987 and 1992.

At the start of the study, 300 participants had glaucoma, including 141 who had been diagnosed and treated. After 9 years, 764 of the participants had died. The risk of death from cardiovascular causes was 38% higher in people who had previously been diagnosed with or treated for open-angle glaucoma and 91% higher in those who had been treated with timolol drops.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.